Lhotse Bio Inc. has described lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of cancer, fibrosis, inflammatory disorders, multiple sclerosis, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly nonalcoholic fatty liver disease [NAFLD]), osteoporosis, SARS-CoV-2 infection (COVID-19) and transplant rejection.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has synthesized cyclin-dependent kinase 8 (CDK8) and/or CDK19 inhibitors reported to be useful for the treatment of cancer.
Daegu-Gyeongbuk Medical Innovation Foundation has disclosed estrogen receptor α (ER-α; ESR1) antagonists reported to be useful for the treatment of cancer.
Researchers from Philochem AG recently reported the discovered OncoFAP, a high-affinity small organic ligand of fibroblast activation protein (FAP) that has shown rapid accumulation in tumors and low uptake in healthy tissues in preclinical models.
Angiogenesis plays a crucial role in multiple myeloma and its prognosis, with the success of antiangiogenic therapies being limited. Exosomes mediate cell-to-cell cross talk during the progression of cancer by transporting their molecular cargo, which include long non-coding RNAs (lncRNAs); their role in multiple myeloma was investigated.
Revir Therapeutics Inc. has announced the achievement of a milestone under its ongoing collaboration with Asieris Pharmaceuticals Co. Ltd. to develop treatments for cancers using a novel target.
The development of resistance and relapse during the blast phase of chronic myeloid leukemia poses a challenge in the management of this pathology, with half of the cases accounting for FLT3 pathway activation that, in turn, contributes to tyrosine kinase inhibitor resistance.
B-cell lymphoma 6 (BCL6) is up-regulated in several B-cell malignancies where it acts as a transcription factor activity mediator to induce and maintain lymphomagenesis.
RSS
